Anne Huyn
7 Papers
13 Citations
Anne Huyn is an academic researcher. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 4, co-authored 7 publications.
Chat about Author
Papers
Allogeneic Hematopoietic Stem-Cell Transplantation After Nonmyeloablative Preparative Regimens: Impact of Pretransplantation and Posttransplantation Factors on Outcome
Mauricette Michallet,Karin Bilger,Frédéric Garban,Michel Attal,Anne Huyn,Didier Blaise,Noel Milpied,Philippe Moreau,Pierre Bordigoni,M. Kuentz,A Sadoun,Jean-Yves Cahn,Gérard Socié,Xavier Thomas,Philippe Arnaud,Nicole Raus,Véronique Lhéritier,Arnaud Pigneux,Jean-Michel Boiron +18 more
TL;DR: This series shows encouraging results from nonmyeloablative conditioning regimens before allotransplantation and demonstrates the impact of some pre- and posttransplantation factors on outcome after transplantation.
93
In patients older than 55 years with AML in first CR, should we search for a matched unrelated donor when an old sibling donor is available?
R. Peffault de Latour,M. Labopin,Jonathan Cornelissen,Stephane Vigouroux,Charles Craddock,Didier Blaise,Anne Huyn,Lars Vindeløv,Johan Maertens,Patrice Chevallier,Nathalie Fegueux,Gérard Socié,Gérard Socié,J.Y. Cahn,Eefke Petersen,Harry C. Schouten,Bruno Lioure,Nigel H. Russell,Lucía López Corral,Fabio Ciceri,Arnon Nagler,M. Mohty +21 more
TL;DR: HLA-identical sibling donors aged55 years or more should not be excluded because of age for patients aged 55 years and older with AML in CR1, and 3-year overall survival was 49% with both MSD and MUD.
18
Hematopoietic Stem Cell Transplantation in Multiple Myeloma: A Retrospective Study of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC)
Yvan Beaussant,Etienne Daguindau,Aurore Pugin,Mohamad Mohty,Hervé Avet-Loiseau,Damien Roos-Weil,Mauricette Michallet,Patrice Chevalier,Nicole Raus,Jean El-Cheikh,Reza Tabrizi,Anne Huyn,Agnès Buzyn,Gérard Socié,Laure Vincent,François Guilhot,Ibrahim Yakoub-Agha,Pascal Lenain,Sylvie François,Florence Beckerich,Bruno Lioure,Claude-Eric Bulabois,Eric Deconinck +22 more
TL;DR: It is indicated that MAC should remain a valuable option in alloSCT for MM, especially for young and less-treated patient with no comorbidity, and outcomes were not affected by conditioning intensity either on univariate or multivariate analysis.
13
Equivalent Outcome Between Older Siblings and Unrelated Donors After Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Patients Older Than 50 Years with Acute Myeloid Leukemia in First Complete Remission: A Report From the ALWP of EBMT
Régis Peffault de Latour,Myriam Labopin,Jan J. Cornelissen,Lars Vindeløv,Didier Blaise,Noel Milpied,Anne Huyn,Charles Craddock,Nigel H Russel,Vladimir Koza,Bruno Lioure,Richard Schouten,Dolores Caballero,Jean-Yves Cahn,Nathalie Fegueux,Mohamad Mohty +15 more
TL;DR: The recommendation to consider HLA-identical donors for HSCT even after 60 years of age (if eligible for donation) prior to younger 8/8 MUD for pts with AML older than 50 years in CR1 after a RIC regimen is supported.
5
O-014 Azacitidine versus best supportive care before non-myeloablative allogeneic stem cell transplantation for MDS: A study by the SFGM-TC
G. Damaj,A. Duhame,M. Robin,Noel Milpied,Mauricette Michallet,Patrice Chevallier,Yves Beguin,Son Nguyen,Bruno Lioure,Didier Blaise,Natacha Maillard,Marie T Rubio,Nathalie Fegueux,Jérôme Cornillon,Sylvie François,Mohamad Mohty,Anne Huyn,Claude-Eric Bulabois,Pierre Fenaux,Ibrahim Yakoub-Agha +19 more
1